

VPA10405/005/001

Avishield IB GI-13, lyophilisate for ocular suspension/use in drinking water for chickens

Variation	Summary	Date
B.I.b.1.d	IA - B.I.b.1.d - d) Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - B.I.b.1.d - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	24/03/22
B.I.b.2.e	IB - B.I.b.2.e - e) Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - B.I.b.2.e - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate	24/03/22
B.I.b.2.e	IB - B.I.b.2.e - e) Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - B.I.b.2.e - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate	24/03/22
B.II.d.1.f	II - B.II.d.1.f - f) Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product - B.II.d.1.f - QUALITY CHANGES - FINISHED PRODUCT - Control of finished product - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product	24/03/22
C.I.4	II - C.I.4 - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - C.I.4 - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - HUMAN AND VETERINARY MEDICINAL PRODUCTS - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data	10/03/22